2022 was a rough year for much of the pharma sector, with limited M&A, IPO, and venture financing activity. With Q1 now over, are we expecting to see an improvement in the business of pharma? The collapse of SVP was hardly an auspicious start, but the fallout from that may not be felt until further down the line. 

At this stage, it’s not looking good. Big pharma’s position as a safe haven is now pretty shaky with some of the biggest players on the planet seeing their market cap drop in the first three months of the year. The best that can be said of the IPO scene for the quarter is that it was better than the prior three months – and if that sounds like faint praise, it is. 



A lean first quarter for venture-backed developers
Biopharma stocks go back to bleak
Floating biotechs prompt tiny sparks of hope
The Covid crash continues